Home |  English version |  Mappa |  Commenti |  Sondaggio |  Staff |  Contattaci Cerca nel sito  
Istituto di scienza dell'alimentazione

Torna all'elenco Contributi in rivista anno 2010

Contributo in rivista

Tipo: Articolo in rivista

Titolo: Exploring death receptor pathways as selective targets in cancer therapy

Anno di pubblicazione: 2010

Formato: Elettronico Cartaceo

Autori: Russo, M. Mupo, A. Spagnuolo, C. Russo, G. L.

Affiliazioni autori: Istituto Scienze dell'Alimentazione

Autori CNR:


Lingua: inglese

Abstract: A recent and innovative strategy in cancer therapy is the activation of apoptosis in tumour cells specifically expressing death receptors (DR) belonging to the tumour necrosis factor (TNF) receptor superfamily and including several members known since the early '90. Among these, those largely studied for clinical purpose are TNF, CD95, and TRAIL receptors. Promising results are expecting from ongoing phases I/II clinical trials proving the therapeutic efficacy of DR agonistic antibodies and/or recombinant proteins alone or in association to classic and novel chemotherapeutic drugs. However, two key issues need extensive studies, before clinical and safe applications of DRs as effective anticancer drugs can be accepted: i. DR-based cancer therapy must be selective and effective against a broad range of cancers and reduce excessive systemic toxicity toward normal cells and tumour resistance after recurrent treatments; ii. an improved knowledge of mechanisms of alternative signalling triggered by DR ligands and leading to cell survival and apoptotic resistance. Activation of survival pathways regulated by key factors, such as NF-κB, JNK, p38, ERK and PI3K are the focus of several studies revealing the dark side of DR signalling. The present review focuses on new insights in the signalling and clinical application of TNF, CD95 and TRAIL receptors.

Lingua abstract: inglese

Pagine da: 674

Pagine a: 682


Biochemical pharmacology Pergamon Press,
Paese di pubblicazione: Regno Unito
Lingua: inglese
ISSN: 0006-2952

Numero volume: 80

Numero fascicolo: 5

DOI: 10.1016/j.bcp.2010.03.011

Referee: S: Internazionale

Indicizzato da:

  • ISI Web of Science (WOS) [000280024800015]
  • PubMed [20302848]
  • Scopus [2-s2.0-77954216210]

Parole chiave:

  • CD95
  • Cancer therapy
  • TRAIL CD95/Fas TNF-alpha
  • Death receptors

Strutture CNR:


Torna indietro Richiedi modifiche Invia per email Stampa
Home Il CNR  |  I servizi News |   Eventi | Istituti |  Focus